GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Cyclically Adjusted PS Ratio

Jazz Pharmaceuticals (FRA:J7Z) Cyclically Adjusted PS Ratio : 2.54 (As of May. 18, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-18), Jazz Pharmaceuticals's current share price is €99.60. Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €39.28. Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 2.54.

The historical rank and industry rank for Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:J7Z' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.59   Med: 7.62   Max: 27.55
Current: 2.6

During the past years, Jazz Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 27.55. The lowest was 2.59. And the median was 7.62.

FRA:J7Z's Cyclically Adjusted PS Ratio is ranked better than
68.03% of 513 companies
in the Biotechnology industry
Industry Median: 5.51 vs FRA:J7Z: 2.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €13.269. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €39.28 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.64 7.16 4.40 4.41 2.97

Jazz Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 3.16 3.20 2.97 2.84

Competitive Comparison of Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=99.60/39.28
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Jazz Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.269/120.9901*120.9901
=13.269

Current CPI (Mar. 2024) = 120.9901.

Jazz Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.436 100.773 4.125
201409 3.796 100.474 4.571
201412 3.692 99.576 4.486
201503 4.539 99.975 5.493
201506 4.713 100.573 5.670
201509 4.809 100.274 5.803
201512 4.973 99.676 6.036
201603 4.819 99.676 5.849
201606 5.468 101.072 6.546
201609 5.395 100.274 6.510
201612 6.161 99.676 7.478
201703 5.747 100.374 6.927
201706 5.711 100.673 6.864
201709 5.624 100.474 6.772
201712 6.027 100.075 7.287
201803 5.894 100.573 7.091
201806 6.973 101.072 8.347
201809 6.503 101.371 7.762
201812 6.933 100.773 8.324
201903 7.743 101.670 9.214
201906 8.231 102.168 9.747
201909 8.500 102.268 10.056
201912 9.144 102.068 10.839
202003 8.648 102.367 10.221
202006 8.940 101.769 10.628
202009 9.072 101.072 10.860
202012 9.568 101.072 11.454
202103 8.740 102.367 10.330
202106 10.497 103.364 12.287
202109 11.625 104.859 13.413
202112 12.899 106.653 14.633
202203 11.745 109.245 13.008
202206 13.913 112.779 14.926
202209 15.132 113.504 16.130
202212 14.552 115.436 15.252
202303 11.304 117.609 11.629
202306 12.015 119.662 12.148
202309 12.777 120.749 12.803
202312 13.320 120.749 13.347
202403 13.269 120.990 13.269

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jazz Pharmaceuticals  (FRA:J7Z) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (FRA:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines